Compare AbCellera Biologics Inc (ABCL) vs Booking Holdings Inc (BKNG) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs Booking Holdings Inc — how do they compare? AbCellera Biologics Inc trades at $7.18 (market cap $2.35B), while Booking Holdings Inc trades at $173.35 (market cap $140.99B). The key difference: Booking Holdings Inc is far larger — about 60× AbCellera Biologics Inc's market cap, and Booking Holdings Inc pays a 0.88% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | BKNG | |
|---|---|---|
Market Cap | $2.35B | $140.99B |
Sector | Health | Consumer Cyclical |
52-Week High | $8.12 | $231.02 |
52-Week Low | $2.78 | $154.13 |
Enterprise Value | $1.99B | $143.91B |
Dividend Yield | — | 0.88% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
Booking Holdings (BKNG) trades at $181.95, down 1.41% on the day, with a bullish technical signal from moving averages. The company demonstrates strong fundamentals with 2025 revenue of $26.92B and net income margin of 22.23%, though Q2 2026 earnings are pending. Analyst consensus remains strongly positive with 64% buy ratings and a $225 price target, representing 24% upside potential from current levels.
BKNG presents a compelling investment case with robust cash flow generation ($9.4B operating cash flow in 2025) and dominant market position, though risks include high debt levels (64% debt-to-asset ratio) and AI disruption concerns. The stock's current valuation at 23.87 P/E appears reasonable given growth prospects, with upcoming Q2 earnings on August 4 serving as the next key catalyst.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Booking Holdings Inc
Booking is the world's largest online travel agency by revenue, offering booking and payment services for hotel and alternative accommodation rooms, airline tickets, rental cars, restaurant reservations, cruises, experiences, and other vacation packages. The company operates a number of branded travel booking sites, including Booking.com, Agoda, OpenTable, and Rentalcars.com, and has expanded into travel media with the acquisitions of Kayak and Momondo. Transaction fees for online bookings account for the bulk of revenue and profits.
Read more on BKNG →
